NFKB1 and acute lymphoblastic leukemia: Besides, GSIs are combined with other targeted therapeutic drugs that can cause T-ALL in a series of studies, such as PI3K-AKT-mTOR pathway inhibitors and NF-κB inhibitors, hoping to achieve a better therapeutic effect [75-81].